6.
Weetman A
. Cellular immune responses in autoimmune thyroid disease. Clin Endocrinol (Oxf). 2004; 61(4):405-13.
DOI: 10.1111/j.1365-2265.2004.02085.x.
View
7.
Zhao H, Xu Y, Cui J
. CXCR2 (rs3890158 and rs2230054) and CXCL4 (rs352008 and rs1801572) gene polymorphisms in patients with thoracic aortic aneurysm. Biotechnol Genet Eng Rev. 2023; 40(4):4300-4312.
DOI: 10.1080/02648725.2023.2210011.
View
8.
Antonelli A, Ferrari S, Corrado A, Ferrannini E, Fallahi P
. Increase of interferon-γ inducible CXCL9 and CXCL11 serum levels in patients with active Graves' disease and modulation by methimazole therapy. Thyroid. 2013; 23(11):1461-9.
DOI: 10.1089/thy.2012.0485.
View
9.
. Classification of eye changes of Graves' disease. Thyroid. 1992; 2(3):235-6.
DOI: 10.1089/thy.1992.2.235.
View
10.
Menyhart O, Weltz B, Gyorffy B
. MultipleTesting.com: A tool for life science researchers for multiple hypothesis testing correction. PLoS One. 2021; 16(6):e0245824.
PMC: 8189492.
DOI: 10.1371/journal.pone.0245824.
View
11.
Romagnani P, Rotondi M, Lazzeri E, Lasagni L, Francalanci M, Buonamano A
. Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease. Am J Pathol. 2002; 161(1):195-206.
PMC: 1850693.
DOI: 10.1016/S0002-9440(10)64171-5.
View
12.
Hu D, Wang H, Huang X, Jiang Y, Qin Y, Xiong B
. Investigation of association between IL-8 serum levels and IL8 polymorphisms in Chinese patients with sepsis. Gene. 2016; 594(1):165-170.
DOI: 10.1016/j.gene.2016.09.024.
View
13.
Antonelli A, Rotondi M, Ferrari S, Fallahi P, Romagnani P, Sellari Franceschini S
. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab. 2005; 91(2):614-20.
DOI: 10.1210/jc.2005-1689.
View
14.
Zang F, Yue M, Zhuo L, Wu J, Liu M, Yao Y
. Association of CXCR2 genotype variations with HCV clearance in a Chinese population. Arch Virol. 2018; 163(10):2711-2718.
DOI: 10.1007/s00705-018-3872-0.
View
15.
Antonelli A, Ferrari S, Frascerra S, Pupilli C, Mancusi C, Metelli M
. CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes. J Clin Endocrinol Metab. 2010; 95(12):E413-20.
DOI: 10.1210/jc.2010-0923.
View
16.
Frecker M, STENSZKY V, Balazs C, Kozma L, Kraszits E, Farid N
. Genetic factors in Graves' ophthalmopathy. Clin Endocrinol (Oxf). 1986; 25(5):479-85.
DOI: 10.1111/j.1365-2265.1986.tb03599.x.
View
17.
Yin X, Sachidanandam R, Morshed S, Latif R, Shi R, Davies T
. mRNA-Seq reveals novel molecular mechanisms and a robust fingerprint in Graves' disease. J Clin Endocrinol Metab. 2014; 99(10):E2076-83.
PMC: 4184074.
DOI: 10.1210/jc.2014-1735.
View
18.
Ashhab Y, Dominguez O, Sospedra M, Lucas-Martin A, Pujol-Borrell R
. A one-tube polymerase chain reaction protocol demonstrates CC chemokine overexpression in Graves' disease glands. J Clin Endocrinol Metab. 1999; 84(8):2873-82.
DOI: 10.1210/jcem.84.8.5909.
View
19.
Baek I, Choi E, Shin D, Kim H, Choi H, Kim T
. Distributions of HLA-A, -B, and -DRB1 alleles typed by amplicon-based next generation sequencing in Korean volunteer donors for unrelated hematopoietic stem cell transplantation. HLA. 2020; 97(2):112-126.
DOI: 10.1111/tan.14134.
View
20.
Sokol C, Luster A
. The chemokine system in innate immunity. Cold Spring Harb Perspect Biol. 2015; 7(5).
PMC: 4448619.
DOI: 10.1101/cshperspect.a016303.
View